Co-Diagnostics, Inc.

Co-Diagnostics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0. The balance sheet holds $8.23 million in cash and equivalents against $5.46 million in total liabilities, resulting in a current ratio of 2.28. However, the company faces high liquidity risk due to substantial operating cash burn of $7.85 million in Q1 2026. Management has disclosed going-concern language, citing conditions that raise substantial doubt about the company’s ability to continue as a going concern within one year. To mitigate this, the company raised $4.33 million through an at-the-market (ATM) offering in Q1 2026, which significantly increased shares outstanding from 2.10 million to 3.60 million.

Profitability remains deeply negative, with a net loss of $9.14 million and an operating loss of $9.21 million in Q1 2026. Return on equity stands at -2.92x and return on assets at -2.18x, reflecting the early-stage, cash-intensive nature of the business. Gross profit was negative $47,814, indicating that cost of goods sold exceeded product revenue, likely due to high manufacturing or inventory obsolescence costs relative to sales volume. The company’s market capitalization of $3.25 million trades at a price-to-book ratio of 0.37, suggesting the market values the equity below its book value.

Revenue concentration is high, with significant exposure to government grants and a limited number of customers. Filing data indicates customer concentration risk, with specific tags for "One Customers" and "Two Customers" in accounts receivable and sales revenue. Geographic exposure is split between the US and non-US regions, with specific revenue lines for both domestic and international product and grant sales. The company also holds an investment in joint ventures, including Co-Sara Diagnostics Pvt Ltd, which contributes to non-operating income/loss.

Growth trajectory is characterized by volatility and reliance on capital raises rather than organic revenue expansion. Q1 2026 revenue was $145,954, a modest figure compared to the $9.14 million net loss. The company’s cash position declined from $11.88 million at the end of 2025 to $8.23 million in Q1 2026, despite the $4.33 million ATM raise. This indicates that operating losses are consuming cash reserves rapidly, necessitating continuous equity issuance to fund operations.

Key risks include high dilution risk, as evidenced by the 71% increase in basic shares outstanding in Q1 2026 alone. The company faces medium dilution risk overall, with source documents mentioning offering risk. Additionally, the going-concern warning highlights the fragility of the current financial position. The company’s reliance on ATM offerings for liquidity introduces ongoing pressure on shareholder value.

Recent events include the filing of an 8-K with high severity items related to material agreements and changes in financial statements. The company also disclosed a strategic focus on a multiplex test targeting influenza A/B, COVID-19, and RSV, aligning with clinical demand for comprehensive upper respiratory infection testing. Analyst sentiment is neutral, with a mean recommendation of 3.00 (Hold) and no strong buy or sell ratings.

Revenue $146.0k; Operating income -$9.2M.

• ▍Revenue $146.0k
• ▍Operating income -$9.2M
• ▍Net margin -6262.3%

Revenue $358.6k; Operating income -$23.6M.

• ▍Revenue $358.6k
• ▍Operating income -$23.6M
• ▍Net margin -5898.5%

Revenue $213.2k; Operating income -$16.6M.

• ▍Revenue $213.2k
• ▍Operating income -$16.6M
• ▍Net margin -7159.6%

Revenue $622.5k; Operating income -$50.2M.

• ▍Revenue $622.5k
• ▍Operating income -$50.2M
• ▍Net margin -7533.6%

Revenue $3.9M; Operating income -$40.1M.

• ▍Revenue $3.9M
• ▍Operating income -$40.1M
• ▍Net margin -961.4%

Revenue $3.9M; Operating income -$40.1M.

• ▍Revenue $3.9M
• ▍Operating income -$40.1M
• ▍Net margin -961.4%

Revenue $6.8M; Operating income -$42.7M.

• ▍Revenue $6.8M
• ▍Operating income -$42.7M
• ▍Net margin -518.7%